Cargando…

Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade

Peripheral-immune-checkpoint blockade (P-ICB) with mAbs to PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab, durvalumab, avelumab) alone or combination with chemotherapy represents a novel active treatment for mNSCLC patients. However, this therapy can be associated to immune-related advers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nardone, Valerio, Giannicola, Rocco, Bianco, Giovanna, Giannarelli, Diana, Tini, Paolo, Pastina, Pierpaolo, Falzea, Antonia Consuelo, Macheda, Sebastiano, Caraglia, Michele, Luce, Amalia, Zappavigna, Silvia, Mutti, Luciano, Pirtoli, Luigi, Giordano, Antonio, Correale, Pierpaolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236817/ https://www.ncbi.nlm.nih.gov/pubmed/34195086 http://dx.doi.org/10.3389/fonc.2021.684110

Ejemplares similares

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
por: Nardone, Valerio, et al.
Publicado: (2021)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
por: Correale, Pierpaolo, et al.
Publicado: (2020)

How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies
por: Nardone, Valerio, et al.
Publicado: (2018)

The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
por: Nardone, Valerio, et al.
Publicado: (2023)

PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach
por: Fameli, Antonella, et al.
Publicado: (2022)

CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
por: Nardone, Valerio, et al.
Publicado: (2021)

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine
por: Correale, Pierpaolo, et al.
Publicado: (2018)

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
por: Pastina, Pierpaolo, et al.
Publicado: (2017)

Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy
por: Tini, Paolo, et al.
Publicado: (2017)

Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation
por: Nardone, Valerio, et al.
Publicado: (2019)

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up
por: Caraglia, Michele, et al.
Publicado: (2019)

Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
por: Della Corte, Carminia Maria, et al.
Publicado: (2019)

Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune–Biological Evaluation and Case Report
por: Botta, Cirino, et al.
Publicado: (2021)

Inflammatory status affects the antitumor activity of poly-epitope-peptide vaccination against the thymidylate synthase in metastatic colo-rectal cancer patients enrolled in TSPP/VAC-1 Phase Ib trial
por: Correale, Pierpaolo, et al.
Publicado: (2015)

Combined Epidermal Growth Factor Receptor and Beclin1 Autophagic Protein Expression Analysis Identifies Different Clinical Presentations, Responses to Chemo- and Radiotherapy, and Prognosis in Glioblastoma
por: Tini, Paolo, et al.
Publicado: (2015)

Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients
por: Caracciolo, Massimo, et al.
Publicado: (2021)

Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
por: Meirson, Tomer, et al.
Publicado: (2022)

Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
por: Tenti, Sara, et al.
Publicado: (2020)

Prognostic Value of MR Imaging Texture Analysis in Brain Non-Small Cell Lung Cancer Oligo-Metastases Undergoing Stereotactic Irradiation
por: Nardone, Valerio, et al.
Publicado: (2016)

Body Composition Findings by Computed Tomography in SARS-CoV-2 Patients: Increased Risk of Muscle Wasting in Obesity
por: Gualtieri, Paola, et al.
Publicado: (2020)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Extracellular Vesicles: New Endogenous Shuttles for miRNAs in Cancer Diagnosis and Therapy?
por: Martellucci, Stefano, et al.
Publicado: (2020)

HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
por: Jimbu, Laura, et al.
Publicado: (2021)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report
por: d’Apolito, Maria, et al.
Publicado: (2022)

Combination CD200R/PD-1 blockade in a humanised mouse model
por: Fellermeyer, Martin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1t0adloh9ttedlakj9dcqv1j0u